The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension



Status:Recruiting
Conditions:High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 75
Updated:12/22/2018
Start Date:May 1, 2016
End Date:December 31, 2019
Contact:Loic Perchenet
Email:loic.perchenet@actelion.com

Use our guide to learn which trials are right for you!

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

The objective of this clinical trial is to compare the efficacy and safety of an initial
triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral
treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve
patients with pulmonary arterial hypertension.


Inclusion Criteria:

1. Signed informed consent prior to any study-mandated procedure.

2. Male or female ≥ 18 and ≤ 75 years of age at screening.

3. Initial PAH diagnosis < 6 months prior to enrollment.

4. RHC performed between Day −28 and Day 1, meeting all the following criteria:

- Mean pulmonary artery pressure (mPAP) ≥ 25 mmHg.

- Pulmonary artery wedge pressure or left ventricular end-diastolic pressure ≤ 15
mmHg.

- PVR ≥ 480 dyn•sec/cm5 (≥ 6 Wood Units).

- Negative vasoreactivity test mandatory in idiopathic, heritable, and drug/toxin
induced PAH (at this or a previous RHC).

5. Symptomatic PAH belonging to one of the following subgroups:

- Idiopathic.

- Heritable.

- Drug or toxin induced.

- Associated with one of the following: connective tissue disease; HIV infection;
congenital heart disease.

6. 6-minute walk distance (6MWD) ≥ 50 m at screening.

7. Women of childbearing potential must not be pregnant, must perform regular pregnancy
tests, and use reliable contraception.

Exclusion Criteria:

1. Any PAH-specific drug therapy at any time.

2. Cardio pulmonary rehabilitation program based on exercise (planned, or started ≤ 12
weeks prior to Day 1).

3. Body mass index (BMI) > 40 kg/m2 at screening.

4. Presence of three or more of the following risk factors for heart failure with
preserved ejection fraction at screening:

- BMI > 30 kg/m2.

- Diabetes mellitus of any type.

- Essential hypertension.

- Coronary artery disease, i.e., any of the following:

- History of stable angina or

- More than 50% stenosis in a coronary artery (by coronary angiography) or

- History of myocardial infarction or

- History of or planned coronary artery bypass grafting and/or coronary artery
stenting.

5. Acute myocardial infarction ≤ 12 weeks prior to screening.

6. Stroke ≤ 12 weeks prior to screening.

7. Known permanent atrial fibrillation.

8. SBP < 90 mmHg at screening or Day 1.

9. Ongoing or planned treatment with organic nitrates and/or doxazosin.

10. Presence of one or more of the following signs of relevant lung disease at any time up
to screening:

- Diffusing capacity of the lung for carbon monoxide (DLCO) < 40% of predicted
(eligible only if no or mild interstitial lung disease on computed tomography).

- Forced vital capacity (FVC) < 60% of predicted.

- Forced expiratory volume in one second (FEV1) < 60% of predicted.

11. Known or suspected pulmonary veno-occlusive disease (PVOD).

12. Documented severe hepatic impairment (with or without cirrhosis) according to National
Cancer Institute organ dysfunction working group criteria, defined as total bilirubin
> 3 × upper limit of the normal range (ULN) accompanied by aspartate aminotransferase
(AST) > ULN (assessed by central laboratory at screening); and/or Child-Pugh Class C.

13. Serum AST and/or alanine aminotransferase (ALT) > 3 × ULN (assessed by central
laboratory at screening).

14. Severe renal impairment (estimated creatinine clearance ≤ 30 mL/min/1.73 m2) assessed
by central laboratory at screening.

15. Ongoing or planned dialysis.

16. Hemoglobin < 100 g/L assessed by central laboratory at screening.

17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).

18. Loss of vision in one or both eyes because of non-arteritic ischemic optic neuropathy
(NAION).

19. Treatment with strong inducers of cytochrome P450 3A4 (CYP3A4; e.g., carbamazepine,
rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's
wort) ≤ 28 days prior to Day 1.

20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,
voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
and/or strong inhibitors of CYP2C8 (e.g., gemfibrozil) ≤ 28 days prior to Day 1.

21. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to Day
1).

22. Hypersensitivity to any of the 3 study treatments or any excipient of their
formulations.

23. Pregnancy, breastfeeding, or intention to become pregnant during the study.

24. Concomitant life-threatening disease with a life expectancy < 12 months.

25. Alcohol abuse.

26. Any factor or condition likely to affect protocol compliance of the subject, as judged
by the investigator.
We found this trial at
21
sites
Baltimore, Maryland 21287
Phone: 410-614-6311
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Phone: 617-636-4288
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
2950 Cleveland Clinic Blvd.
Weston, Florida 33331
866.293.7866
Phone: 954-659-5450
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
?
mi
from
Weston, FL
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
Phone: 734-938-5383
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30309
Phone: 404-350-0009
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1 Boston Medical Center Place
Boston, Massachusetts 02118
617.638.8000
Phone: 617-638-4860
Boston University Medical Center Boston Medical Center is an extraordinary community of health care providers...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Camperdown, New South Wales
Phone: +61 407 892217
?
mi
from
Camperdown,
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Phone: 312-926-7755
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2139 Auburn Ave
Cincinnati, Ohio 45219
(513) 585-2000
Phone: 513-244-9096
The Christ Hospital For more than 120 years, The Christ Hospital has been a leader...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Phone: 214-645-6491
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Phone: 713-441-7182
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
Phone: 319-353-8117
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Jacksonville, Florida 32216
Phone: 904-953-2381
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
La Jolla, California 92093
Phone: 858-657-7150
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
757 Westwood Plaza
Los Angeles, California 90024
(310) 825-9111
Phone: 310-267-7492
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Phone: 502-587-8000
?
mi
from
Louisville, KY
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Phone: 505-272-4751
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Phoenix, Arizona 85013
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15212
Phone: 412-359-4760
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Phone: 412-647-7168
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Michigan 63110
Phone: 314-454-8766
?
mi
from
Saint Louis, MI
Click here to add this to my saved trials